{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045378385408.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1097/iae.0b013e318236e503"}},{"identifier":{"@type":"URI","@value":"http://journals.lww.com/00001665-201203000-00091"}},{"identifier":{"@type":"PMID","@value":"22446886"}}],"dc:title":[{"@value":"INTRAVITREAL RANIBIZUMAB FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH GOOD BASELINE VISUAL ACUITY"}],"description":[{"notation":[{"@value":"To clarify the efficacy of ranibizumab for treating age-related macular degeneration in patients with baseline visual acuity exceeding 20/40.We retrospectively reviewed 40 eyes of Japanese patients with age-related macular degeneration (32 men, 8 women) treated with intravitreal injections of ranibizumab (0.5 mg/0.05 mL) (ranibizumab group). We compared the results with observation of 52 eyes (control group). All patients were followed-up for at least 12 months.In the ranibizumab group, the mean logarithm of the minimum angle of resolution best-corrected visual acuity (Snellen equivalent) with typical age-related macular degeneration (22 eyes) and polypoidal choroidal vasculopathy (18 eyes) statistically significantly (P0.0001, P = 0.015, respectively) improved from 0.17 (20/29) and 0.14 (20/28) at baseline to 0.07 (20/24) and 0.07 (20/24) at Month 12, respectively (mean numbers of treatments, 4.6 and 4.9). The central retinal thickness decreased from 262 ± 105 μm at baseline to 187 ± 62 μm at Month 12 in the ranibizumab group. In the control group, the mean logarithm of the minimum angle of resolution best-corrected visual acuity in eyes with typical age-related macular degeneration (19 eyes) and polypoidal choroidal vasculopathy (33 eyes) statistically significant (P = 0.017, P = 0.023, respectively) declined from 0.08 (20/24) and 0.10 (20/25) at baseline to 0.18 (20/30) and 0.23 (20/34) at Month 12, respectively.Intravitreal ranibizumab maintained or improved visual acuity and anatomic changes in patients with age-related macular degeneration with better than 20/40 visual acuity."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381137045378385409","@type":"Researcher","foaf:name":[{"@value":"Masaaki Saito"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045378385408","@type":"Researcher","foaf:name":[{"@value":"Tomohiro Iida"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045378385536","@type":"Researcher","foaf:name":[{"@value":"Mariko Kano"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0275004X"}],"prism:publicationName":[{"@value":"Retina"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2012-07","prism:volume":"32","prism:number":"7","prism:startingPage":"1250","prism:endingPage":"1259"},"reviewed":"false","url":[{"@id":"http://journals.lww.com/00001665-201203000-00091"}],"createdAt":"2012-03-23","modifiedAt":"2021-04-13","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Aged,%2080%20and%20over","dc:title":"Aged, 80 and over"},{"@id":"https://cir.nii.ac.jp/all?q=Indocyanine%20Green","dc:title":"Indocyanine Green"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Vascular%20Endothelial%20Growth%20Factor%20A","dc:title":"Vascular Endothelial Growth Factor A"},{"@id":"https://cir.nii.ac.jp/all?q=Visual%20Acuity","dc:title":"Visual Acuity"},{"@id":"https://cir.nii.ac.jp/all?q=Angiogenesis%20Inhibitors","dc:title":"Angiogenesis Inhibitors"},{"@id":"https://cir.nii.ac.jp/all?q=Exudates%20and%20Transudates","dc:title":"Exudates and Transudates"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Antibodies,%20Monoclonal,%20Humanized","dc:title":"Antibodies, Monoclonal, Humanized"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Ranibizumab","dc:title":"Ranibizumab"},{"@id":"https://cir.nii.ac.jp/all?q=Intravitreal%20Injections","dc:title":"Intravitreal Injections"},{"@id":"https://cir.nii.ac.jp/all?q=Wet%20Macular%20Degeneration","dc:title":"Wet Macular Degeneration"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Fluorescein%20Angiography","dc:title":"Fluorescein Angiography"},{"@id":"https://cir.nii.ac.jp/all?q=Coloring%20Agents","dc:title":"Coloring Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Follow-Up%20Studies","dc:title":"Follow-Up Studies"},{"@id":"https://cir.nii.ac.jp/all?q=Retrospective%20Studies","dc:title":"Retrospective Studies"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360285711022476544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181267790080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656244581120","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1361697223510966528","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation"}]},{"@id":"https://cir.nii.ac.jp/crid/1363104598394285312","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation"}]},{"@id":"https://cir.nii.ac.jp/crid/1523669555364359168","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CLINICAL INVESTIGATION : Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1097/iae.0b013e318236e503"},{"@type":"OPENAIRE","@value":"doi_dedup___::39aadbb874e2502eb4749113fc408e9f"},{"@type":"CROSSREF","@value":"10.1136/bjophthalmol-2014-305076_references_DOI_EeaAGnyMc9Yj8xQJ1uV3CoMRCMP"},{"@type":"CROSSREF","@value":"10.1007/s10384-015-0411-3_references_DOI_EeaAGnyMc9Yj8xQJ1uV3CoMRCMP"},{"@type":"CROSSREF","@value":"10.1007/s10384-016-0478-5_references_DOI_EeaAGnyMc9Yj8xQJ1uV3CoMRCMP"},{"@type":"CROSSREF","@value":"10.1007/s10384-013-0245-9_references_DOI_EeaAGnyMc9Yj8xQJ1uV3CoMRCMP"},{"@type":"CROSSREF","@value":"10.1007/s10384-015-0417-x_references_DOI_EeaAGnyMc9Yj8xQJ1uV3CoMRCMP"},{"@type":"CROSSREF","@value":"10.1007/s10384-012-0215-7_references_DOI_EeaAGnyMc9Yj8xQJ1uV3CoMRCMP"}]}